therapeutic-depth cardiovascular 
XTalks
MARCH 7, 2024
These disturbances are linked to insomnia, less restful sleep and potential cardiovascular issues during night-time awakenings. Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinical trial strategies. Through this, researchers can pinpoint breast cancer cell types and their phenotypic states.
Drug Discovery World
NOVEMBER 29, 2023
Letting the AI help examine regular tissues means we will see reduced cost and time, and we will be able to focus our expertise on the slides that need more in-depth analysis. MT: What industry-wide innovation or breakthrough holds the potential to be most impactful to your research?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 13, 2023
Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. DDW: Could you explain the process of transcriptomics? SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. since October 2021.
The Pharma Data
NOVEMBER 1, 2020
CAMBRIDGE, England–( BUSINESS WIRE )– Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect. – ENDS – NOTES TO EDITORS: About Mission Therapeutics.
XTalks
NOVEMBER 7, 2023
Their role encompasses navigating the product development cycle, ensuring effective utilization of products, offering support and scholarly exchange within the medical community and providing in-depth scientific knowledge to their company’s internal teams.
pharmaphorum
OCTOBER 19, 2020
The number of people living with chronic illnesses will rise year-on-year, and the ongoing management of ‘lifestyle’ illnesses like diabetes, obesity and cardiovascular disease will require ever increasing resources. Combining digital therapeutics with pharmaceutical innovations. This is nothing new.
The Pharma Data
MAY 27, 2022
Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Res), EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival.
Expert insights. Personalized for you.
115 
Let's personalize your content